Ozempic vs. Wegovy: Same Drug, Different Purpose

Ozempic and Wegovy are the same drug. Both are semaglutide, manufactured by the same company (Novo Nordisk), delivered through the same once-weekly injection. The difference isn't the molecule. It's the label.

Ozempic is FDA-approved to treat type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Same active ingredient, different indications, different maximum doses, and, critically for most people, very different insurance coverage.

Roughly 1 in 8 U.S. adults say they are currently taking a GLP-1 medication, according to KFF's November 2025 health tracking poll. The two most recognizable brands, by a wide margin, are Ozempic and Wegovy. And despite being pharmacologically identical, they're prescribed for different reasons, priced differently, and covered differently by insurance.

Here's the full breakdown.

Both Ozempic and Wegovy contain semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a hormone your gut produces after you eat. It slows digestion, signals fullness to the brain, and, for most people, makes large meals physically unappealing. We've covered how GLP-1s actually work in a separate guide, but the short version is: same mechanism, same molecular target, same physiological effect.

If you lined up a dose of Ozempic and an equivalent dose of Wegovy in a lab, they'd be indistinguishable. There is no secret "weight loss version" of the molecule. The drug is the drug.

This is where the "different purpose" part comes in, and it's more about FDA regulation and commercial strategy than pharmacology.

When Novo Nordisk first got semaglutide approved in 2017, the approved use was type 2 diabetes. That product was marketed as Ozempic. The clinical trials that earned the approval were the SUSTAIN trial series, which focused on blood sugar control and cardiovascular outcomes in people with diabetes.

But Novo Nordisk's researchers (and frankly, a lot of patients and doctors) noticed quickly that semaglutide produced substantial weight loss as a side effect, even in people without diabetes. So the company ran a separate set of clinical trials, the STEP series, specifically studying semaglutide for obesity and chronic weight management. Those trials supported a new FDA approval in 2021, and that product was marketed as Wegovy.

From the FDA's perspective, these are two different drugs, because they're approved for two different indications, and each indication has its own label, its own dosing protocol, and its own approved patient population. From a chemistry perspective, they're the same thing.

Here's where the two products genuinely diverge in practice.

Ozempic dosing:

Wegovy dosing:

The higher Wegovy ceiling matters. In the STEP 1 trial, participants on 2.4 mg semaglutide lost an average of about 15% of their body weight over 68 weeks, per the New England Journal of Medicine. That dose is not available under the Ozempic label. If your doctor wants to push semaglutide to the level studied for meaningful weight loss, that's Wegovy territory.

This is also why "just take Ozempic for weight loss" is not quite the shortcut some people assume. At Ozempic's maximum dose of 2 mg, you'd be underdosed relative to the clinical evidence for weight management.

Ozempic is approved for:

Wegovy is approved for:

Your doctor can only prescribe a medication "on-label" with confidence that insurance will cover it. Off-label prescribing (for example, Ozempic for weight loss alone) is legal, but insurance usually won't pay.

Without insurance, list prices for both sit in similar territory: roughly $900 to $1,350 per month depending on pharmacy and dosage. Coverage is where most patients feel the gap.

Ozempic is widely covered by commercial insurance and Medicare Part D when prescribed for type 2 diabetes. Wegovy coverage for weight loss is far more variable. Medicare has long been prohibited by law from covering medications specifically for weight loss, though pilot programs are starting to shift that. Medicaid coverage for weight-loss GLP-1s is limited to 13 states as of January 2026, per KFF. Commercial plans are a mixed bag. Some cover Wegovy fully. Others exclude weight-loss drugs entirely.

The practical result: many patients who clinically qualify for Wegovy end up paying cash, exploring compounded alternatives, or going through a telehealth provider for a more predictable monthly rate.

Last verified: April 2026.

Because the molecule is the same, the side effect profile is the same. Nausea is the most common complaint, reported by roughly half of users in RAND's 2025 population-level survey. Diarrhea, vomiting, and reduced appetite follow. Most users describe side effects as mild to moderate, most prominent during dose escalation, and manageable.

There's a reasonable argument that Wegovy users experience side effects slightly more often on average, simply because they're titrated to a higher dose. But the chemistry doesn't change between brands.

This mostly comes down to why you're seeing a doctor in the first place.

A good prescriber will walk you through all three scenarios rather than just writing the first thing that comes to mind. If the provider you're considering skips that conversation, that's a red flag about the provider, not the medication.

Is Wegovy just a higher dose of Ozempic? Functionally, yes. Wegovy is the same semaglutide molecule titrated to a higher maximum dose (2.4 mg vs. 2 mg) and approved for a different condition.

Can you take Ozempic for weight loss? Legally, a doctor can prescribe it off-label, but insurance rarely covers off-label prescriptions, and Ozempic's approved maximum dose is lower than the dose studied for weight loss.

Is one safer than the other? No. Same molecule, same safety profile, same warnings and contraindications.

Is Ozempic cheaper than Wegovy? List prices are similar. Out-of-pocket costs often differ because Ozempic is more broadly covered by insurance when prescribed for diabetes.

Does Wegovy work better than Ozempic for weight loss? At their respective maximum doses, yes. Wegovy's 2.4 mg dose is the one studied in the STEP trials that produced the ~15% average weight loss figure. Ozempic capped at 2 mg produces less pronounced weight loss on average.

Ozempic and Wegovy are the same molecule sold under two labels, approved for two different things. If you're clear on why you're considering a GLP-1, the right choice usually picks itself. If you're not clear, that's the conversation to have with a doctor, not with a telehealth intake form.

Before starting, stopping, or switching any GLP-1 medication, talk to a licensed healthcare provider who will review your medical history, explain your options, and help you weigh the trade-offs. The drug is powerful. The decision deserves a real conversation.